CurrentPartnering

Manufacturing and Supply Agreements in Biopharma
The Manufacturing and Supply Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 1000 links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Distribution Agreements in Biopharma
The Distribution Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter distribution deals.

The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.

Co-promotion and Co-marketing Agreements in Biopharma
The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Merger and Acquisition Agreements in Biopharma
The Merger and Acquisition Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

Bigpharma Partnering Agreements
The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

Practical Guide to Finding Partners in Biopharma
CurrentPartnering’s Practical Guide to Finding Partners in Biopharma provides a comprehensive overview of all the steps required to identify and secure partnering either for an in-licensing or out-licensing activity.

Combined Bigpharma Dealmaking and Agreements Handbook 2007
The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

The combined Bigpharma Dealmaking and Agreements Handbook 2007 provides the entire content of both reports at a great discounted price.

Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

Bigpharma Agreements Handbook 2007
Summary

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Description

Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Bigpharma Dealmaking Handbook 2007
Summary

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Report description

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues.

Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities.

The main body of the report is provided in chapter 7 and 8. Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years. Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which can be obtained from CurrentPartnering, either individually or as part of a contract set. See each company profile for further details.

Formats available: PDF